For most generic firms, the key date for a brand product is usually the end of exclusivity, but Actavis is placing much of its planning emphasis this year on the other end of the lifecycle, a user fee date – specifically June 25, 2012, when it aims to reinvigorate its pain portfolio with the approval of MoxDuo, an immediate-release combination of morphine and oxycodone.
Actavis plans to market the product under a bidding letter of intent signed with QRxPharma Ltd., which developed the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?